1-(anthracene-9-yl)-4,4,4-trifluoro-1,3-butanedione | 18931-63-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 蒽
• 英文名称: 1-(anthracene-9-yl)-4,4,4-trifluoro-1,3-butanedione
• 英文别名: 1-(9-anthryl)-4,4,4-trifluoro-1,3-butanedione；1-(9-Anthracenyl)-4,4,4-trifluoro-1,3-butanedione；1-anthracen-9-yl-4,4,4-trifluorobutane-1,3-dione
• CAS: 18931-63-0
• 化学式: C₁₈H₁₁F₃O₂
• 分子量: 316.279
• InChiKey: YCVRNTDSBSTXKR-UHFFFAOYSA-N

物化性质

• 熔点：
  87-88 °C
• 沸点：
  444.3±40.0 °C(Predicted)
• 密度：
  1.341±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-(anthracene-9-yl)-4,4,4-trifluoro-1,3-butanedione 在 盐酸 、 双氧水 、 sodium carbonate 作用下， 以 乙醇 、 二甲基亚砜 为溶剂， 反应 3.0h， 生成 4-(5-anthracen-9-yl-3-trifluoromethyl-pyrazol-1-yl)-benzamide
  参考文献：
  名称：

  Development of novel antibacterial agents against methicillin-resistant Staphylococcus aureus

  摘要：

  Methicillin-resistant Staphylococcus aureus (MRSA) poses a serious threat to public health because of its resistance to multiple antibiotics most commonly used to treat infection. In this study, we report the unique ability of the cyclooxygenase-2 (COX-2) inhibitor celecoxib to kill Staphylococcus aureus and MRSA with modest potency. We hypothesize that the anti-Staphylococcus activity of celecoxib could be pharmacologically exploited to develop novel anti-MRSA agents with a distinct mechanism. Examination of an in-house, celecoxib-based focused compound library in conjunction with structural modifications led to the identification of compound 46 as the lead agent with high antibacterial potency against a panel of Staphylococcus pathogens and different strains of MRSA. Moreover, this killing effect is bacteria-specific, as human cancer cells are resistant to 46. In addition, a single intraperitoneal administration of compound 46 at 30 mg/kg improved the survival of MRSA-infected C57BL/6 mice. In light of its high potency in eradicating MRSA in vitro and its in vivo activity, compound 46 and its analogues warrant continued preclinical development as a potential therapeutic intervention against MRSA. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.06.018
• 作为产物：
  描述：

  9-乙酰基蒽 、 三氟乙酸乙酯 在 sodium hydride 、 盐酸 作用下， 以 四氢呋喃 、 水 、 乙酸乙酯 为溶剂， 反应 5.0h， 生成 1-(anthracene-9-yl)-4,4,4-trifluoro-1,3-butanedione
  参考文献：
  名称：

  Development of novel antibacterial agents against methicillin-resistant Staphylococcus aureus

  摘要：

  Methicillin-resistant Staphylococcus aureus (MRSA) poses a serious threat to public health because of its resistance to multiple antibiotics most commonly used to treat infection. In this study, we report the unique ability of the cyclooxygenase-2 (COX-2) inhibitor celecoxib to kill Staphylococcus aureus and MRSA with modest potency. We hypothesize that the anti-Staphylococcus activity of celecoxib could be pharmacologically exploited to develop novel anti-MRSA agents with a distinct mechanism. Examination of an in-house, celecoxib-based focused compound library in conjunction with structural modifications led to the identification of compound 46 as the lead agent with high antibacterial potency against a panel of Staphylococcus pathogens and different strains of MRSA. Moreover, this killing effect is bacteria-specific, as human cancer cells are resistant to 46. In addition, a single intraperitoneal administration of compound 46 at 30 mg/kg improved the survival of MRSA-infected C57BL/6 mice. In light of its high potency in eradicating MRSA in vitro and its in vivo activity, compound 46 and its analogues warrant continued preclinical development as a potential therapeutic intervention against MRSA. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.06.018

文献信息

• Photophysical Properties of Near-Infrared-Emitting Ln(III) Complexes with 1-(9-Anthryl)-4,4,4-trifluoro-1,3-butandione (Ln = Nd and Er)
  作者：Min-Kook Nah、Hyung-Gook Cho、Hyun-Jung Kwon、Yeong-Joon Kim、Changmoon Park、Hwan Kyu Kim、Jun-Gill Kang

  DOI：10.1021/jp061959x

  日期：2006.9.1

  properties of Nd(III) and Er(III) complexes with 1-(9-anthryl)-4,4,4-trifluoro-1,3-butandione (9-ATFB). The complexes of [Nd(9-ATFB)4]- and [Er(9-ATFB)4]- produced sensitized near-infrared (NIR) luminescence via the excitation of anthracene. This suggests that the intramolecular energy transfer occurred from the singlet excited state of anthracene to the resonance levels of the metal ions, since the phosphorescence

  我们报告的合成和Nd（III）和Er（III）与1-（9-蒽）-4,4,4-三氟-1,3-丁二酮（9-ATFB）配合物的光物理性质。[Nd（9-ATFB）4]-和[Er（9-ATFB）4]-的络合物通过蒽的激发产生敏化的近红外（NIR）发光。这表明分子内的能量转移是从蒽的单重激发态到金属离子的共振能级发生的，因为在正常条件下，蒽的磷光是被禁止的。观察到的可见光的量子产率表明，[Nd（9-ATFB）4]-的能量转移比[Er（9-ATFB）4]-的能量转移更有效。配合物的NIR发光寿命在微秒范围内。
• STRIZHAKOV, O. D.;STRIZHAKOVA, EH. P.;KRIVITSKIJ, A. P.;AXREM, A. A., VESTSI AN BSSR. CEP. XIM. N.,(1990) N, S. 41-44
  作者：STRIZHAKOV, O. D.、STRIZHAKOVA, EH. P.、KRIVITSKIJ, A. P.、AXREM, A. A.

  DOI：——

  日期：——
• MODIFICATION OF LAYERED SILICATES FOR LUMINESCENCE ACTIVATION
  申请人：Klauth Peter

  公开号：US20120107624A1

  公开（公告）日：2012-05-03

  The invention relates to a method for producing a luminescent layered silicate composite. The method according to the invention is characterized in that at least one luminescent dye, in particular fluorescent dye, on the basis of at least one complex, essentially a chelate complex, of at least one element of the rare earth elements (“rare earth complex”) is introduced between and/or stored in at least two layers of at least one layered silicate (“layered silicate layers”) respectively or that at least one luminescent dye, in particular fluorescent dye, on the basis of at least one complex, essentially a chelate complex, of at least one element of the rare earth elements (“rare earth complex”) is combined with a layered silicate to form a composite. The luminescent layered silicate composite according to the invention can be used for marking objects, for example plastic-based objects, or in the field of bioanalysis.
• Development of novel antibacterial agents against methicillin-resistant Staphylococcus aureus
  作者：Hao-Chieh Chiu、Su-Lin Lee、Naval Kapuriya、Dasheng Wang、Yi-Ru Chen、Sung-Liang Yu、Samuel K. Kulp、Lee-Jene Teng、Ching-Shih Chen

  DOI：10.1016/j.bmc.2012.06.018

  日期：2012.8

  Methicillin-resistant Staphylococcus aureus (MRSA) poses a serious threat to public health because of its resistance to multiple antibiotics most commonly used to treat infection. In this study, we report the unique ability of the cyclooxygenase-2 (COX-2) inhibitor celecoxib to kill Staphylococcus aureus and MRSA with modest potency. We hypothesize that the anti-Staphylococcus activity of celecoxib could be pharmacologically exploited to develop novel anti-MRSA agents with a distinct mechanism. Examination of an in-house, celecoxib-based focused compound library in conjunction with structural modifications led to the identification of compound 46 as the lead agent with high antibacterial potency against a panel of Staphylococcus pathogens and different strains of MRSA. Moreover, this killing effect is bacteria-specific, as human cancer cells are resistant to 46. In addition, a single intraperitoneal administration of compound 46 at 30 mg/kg improved the survival of MRSA-infected C57BL/6 mice. In light of its high potency in eradicating MRSA in vitro and its in vivo activity, compound 46 and its analogues warrant continued preclinical development as a potential therapeutic intervention against MRSA. (C) 2012 Elsevier Ltd. All rights reserved.